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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by defective
extracellular matrix (ECM) turnover as a result of prolonged cigarette smoking. Fibroblasts have a
central role in ECM turnover. The TGFβ induced Smad pathway provides intracellular signals to
regulate ECM production. We address the following hypothesis: fibroblasts have abnormal
expression of genes in the Smad pathway in COPD, resulting in abnormal proteoglycan modulation,
the ground substance of ECM.
Methods: We compared gene expression of the Smad pathway at different time points after
stimulation with TGFβ, TNF or cigarette smoke extract (CSE) in pulmonary fibroblasts of GOLD
stage II and IV COPD patients, and controls.
Results: Without stimulation, all genes were similarly expressed in control and COPD fibroblasts.
TGFβ stimulation: downregulation of Smad3 and upregulation of Smad7 occurred in COPD and
control fibroblasts, indicating a negative feedback loop upon TGFβ stimulation. CSE hardly
influenced gene expression of the TGFβ-Smad pathway in control fibroblasts, whereas it reduced
Smad3 and enhanced Smad7 gene expression in COPD fibroblasts. Furthermore, decorin gene
expression decreased by all stimulations in COPD but not in control fibroblasts.
Conclusion: Fibroblasts of COPD patients and controls differ in their regulation of the Smad
pathway, the contrast being most pronounced under CSE exposure. This aberrant responsiveness
of COPD fibroblasts to CSE might result in an impaired tissue repair capability and is likely
important with regard to the question why only a subset of smokers demonstrates an excess ECM
destruction under influence of cigarette smoking.
Published: 16 December 2008
Respiratory Research 2008, 9:83 doi:10.1186/1465-9921-9-83
Received: 10 April 2008
Accepted: 16 December 2008
This article is available from: http://respiratory-research.com/content/9/1/83
© 2008 Zandvoort et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
Page 2 of 10
(page number not for citation purposes)
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a
severe, slowly progressive and disabling disease associated
with accelerated lung function decline. COPD consists of
emphysema, small airways disease, and chronic bronchi-
tis, which may be present alone or in combination of dif-
ferent intensities. Emphysema is due to an extensive
extracellular matrix (ECM) destruction of lung paren-
chyma [1-5]. In addition, emphysema can coincide with
fibrosis of the airways as observed in chronic bronchitis
and small airways disease [1,6-8]. The generally held
hypothesis is that cigarette smoke induces an excess in
extracellular matrix (ECM) degrading enzymes and reac-
tive oxygen species that subsequently lead to ECM
destruction of lung parenchyma [1]. We here propose a
third important contributing factor to COPD develop-
ment, i.e. an aberrant fibroblast function that contributes
to disturbance of ECM homeostasis.
Pulmonary fibroblasts are essential cells in tissue repair
processes since they are key producers of ECM constitu-
ents [9]. TGFβ is the main cytokine that stimulates fibrob-
lasts to produce ECM constituents like decorin, biglycan,
versican, and collagens [10]. The production of ECM com-
ponents is inhibited by pro-inflammatory cytokines like
TNF and IFN-gamma [11]. We have demonstrated previ-
ously that lung tissue of COPD patients contains less
decorin, an important proteoglycan of the ECM [9,12]. In
addition, our studies have shown that pulmonary fibrob-
lasts of COPD patients with GOLD stage IV (very severe
COPD[13]) produce less decorin after TGFβ stimulation
than those of controls [14]. We hypothesize that this
results from a defect or alteration in gene expression of the
Smad pathway, since this regulates transcription of ECM
proteins like collagens, decorin, versican and biglycan
[11,15-17]. Smads are intracellular signal transducers
transporting the TGFβ activation signal from the receptor
to the nucleus in order to initiate gene transcription of
ECM constituents [11,18-20] (Figure 1). TGFβ interacts
with the TGFβ receptor II which in turn activates TGFβ
receptor I. This activated TGFβ receptor complex induces
phosphorylation of the Smad2-Smad3 complex that can
interact with the transporter Smad4. The resulting com-
plex enters the nucleus and initiates gene transcription of
ECM constituents. Smad7 on the other hand can affect
this pathway by inhibiting phosphorylation of Smad2
and Smad3 and inducing ubiquination of their receptors.
Additionally, Smad7 can induce TGFβ-production by
fibroblasts upon activation by pro-inflammatory
cytokines like TNF and IFN-gamma, thereby enabling
autocrine stimulation that counterbalances superfluous
Smad7 effects [21].
Ideally, fibroblasts should be capable of repairing ciga-
rette smoke induced lung damage. This repair process
appears inadequate in a subset of smokers, leading to
gradually increasing parenchymal ECM destruction and
emphysematous changes [9]. We addressed three ques-
tions to obtain more insight in the underlying mecha-
nisms of this selective susceptibility, following our
hypothesis that the Smad pathway is involved. Because of
the limited knowledge on gene modulation of the Smad
pathway we first addressed the question how Smad path-
way genes are regulated in control fibroblasts under influ-
ence of TGFβ, TNF and cigarette smoke components. We
compared fibroblasts of COPD patients and controls as to
their basal expression of Smad pathway genes. Finally, we
investigated whether TGFβ, TNF and CSE, stimuli that are
of prime importance to fibroblast functioning
[1,2,22,23], stimulate the Smad pathway differently in
primary fibroblast cultures of COPD patients and con-
trols. To analyze Smad gene expression, fibroblasts were
harvested 1 hour, and 24 hours after incubation with
TGFβ, TNF or CSE. Expression of Smad pathway related
genes were analyzed by real-time PCR. As functional read-
out of Smad gene regulation, we determined gene expres-
sion of decorin, versican, and biglycan (Figure 1), ECM
proteoglycans that are relevant to the development of
COPD.
Patients and methods
Study design
To answer the question whether genes of the Smad path-
way are differentially expressed in COPD and controls, we
stimulated primary fibroblasts of patients with stage II
and stage IV COPD and controls with TGFβ, TNF and cig-
arette smoke extract (CSE) for 1, and 24 hours. Primary
fibroblasts were cultured from lung tissue, obtained from
23 individuals. Classification of COPD severity was based
on the 2003 Global initiative for chronic obstructive lung
disease (GOLD) criteria [13]. Three groups were made:
Individuals with moderate (GOLD stage II, n = 9), and
with very severe COPD (stage IV, n = 9), and individuals
with histological normal lungs (n = 5). Patients did not
show clinical signs of chronic bronchitis and were not α1-
antitrypsin deficient. Emphysema was assessed by routine
histological examination of lung tissue, performed by an
experienced pulmonary pathologist (WT). The clinical
characteristics of the groups are presented in table 1.
Informed consent was obtained from all patients. The
study protocol was consistent with national ethical and
professional guidelines ("Code of Conduct; Dutch Feder-
ation of Biomedical Scientific Societies"; http://www.fed
era.org).
Tissue of GOLD stage II COPD patients (median FEV1
73% of predicted) was derived from non-involved lung
tissue from patients undergoing resective surgery for pul-
monary carcinoma. Tissue was always taken as far as pos-
sible from the tumor, or from a non-involved lobe.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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Histopathologically emphysematous lesions were
present, yet of limited but varying severity. The moderate
forms can be histopathologically demonstrated by the
finding of isolated or free-lying segments of viable alveo-
lar septal tissue or isolated cross sections of pulmonary
vessels [19,20].
Tissue of GOLD stage IV COPD patients (median FEV1
19% of predicted) was obtained from COPD patients
undergoing surgery for lung transplantation or lung vol-
ume reduction. All individuals had quitted smoking for at
least 1 year before surgery. The resected tissue showed
both macroscopically and microscopically severe emphy-
sematous lesions, often accompanied by bullae. Sub-pleu-
ral fibrous areas were avoided.
Tissue of the control group (median FEV1 86% of pre-
dicted) was derived from non-involved lung tissue from
patients undergoing resective surgery for pulmonary carci-
noma. Patients had no airway obstruction, nor chronic
airway symptoms like cough and sputum production.
Material was always taken as far as possible from the
tumor, or from a non-involved lobe. No histopathologi-
cal abnormalities were present.
Isolation and culture of lung fibroblasts
Pulmonary fibroblast cultures were established from
parenchymal lung tissue by explant technique. Absence of
mycoplasma contamination in the fibroblast cultures was
confirmed with a mycoplasma detection kit (Roche Diag-
nostics, Almere, The Netherlands). Isolated cells were
Simplified schematic drawing of the TGF-β-Smad pathway Figure 1
Simplified schematic drawing of the TGF-β-Smad pathway. Binding of TGF-β to its type II receptor in concert with the type I 
receptor (A) leads to formation of a receptor complex and phosphorylation of the type I receptor. The type I receptor subse-
quently phosphorylates Smad2 or 3 (B), allowing this complex to associate with Smad4 and move into the nucleus (C). In the 
nucleus, the Smad complex associates with a transcription factor and this complex binds to specific enhancers in target genes 
(down-) regulating transcription (D). TNF is able to interfere with TGF-β signaling through the upregulation of the inhibitory 
Smad7 protein (E). Smad7 is capable of inhibiting the Smad2 and 3 phosphorylating process by competing with the receptor 
interaction but Smad7 also can dephosphorylate the complex. In addition, Smad7 itself is capable to upregulate TGFβ gene 
expression. As described in the discussion, CSE is most likely capable to interfere with the Smad pathway although this is not 
yet fully elucidated. (F). Phosphorylated Smad3 is able to stimulate the transcription of the decorin gene (G). Adapted from 
[18,19,35,36].
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characterized as fibroblasts by morphological appearance
and expression pattern of specific proteins as described
previously [24]. Fibroblast cultures were stored into liquid
nitrogen until use.
Fibroblast cultures cultured in complete culture medium
(Ham's F12, 10%FBS, penicillin, streptavidin and
glutamin (all from Cambrex, Verviers, Belgium)). Experi-
ments were performed on fibroblasts of passage 5/6 with
confluent growth. After reaching confluence, fibroblasts
were cultured for 24 h on 0.5% FBS culture medium
before the stimulations started. Cells were washed with
Ham's culture medium without FBS and incubated with
the appropriate stimulus, diluted in complete culture
medium. TGFβ (R&D systems, Abingdon, UK) was used
in a concentration of 100 u/ml, TNF (R&D systems) in a
concentration of 1000 u/ml and CSE was used in a con-
centration of 2.5%. CSE was prepared according to a
standardized protocol by bubbling the puffs of 4 ciga-
rettes (Kentucky University research cigarettes) through
50 ml of Ham's F12 (Cambrex). The medium was filter
sterilized with a 22 um filter. After the designated dura-
tion of the stimulation (1 and 24 hours) cells were har-
vested by trypsinization (Trypsin, Cambrex) followed by
two wash steps. Non-stimulated fibroblasts were also har-
vested at 1 h and 24 h for comparison of effect of stimula-
tion. Cell pellets were lysed using lysis buffer of the
RNeasy mini kit for RNA isolation (Qiagen, Hilden, Ger-
many). Optimal concentrations and durations of the
stimulation were determined in previous experiments
(data not shown). As a check for an adequate effect of
TGFβ stimulation, expression of plasminogen activator
inhibitor (PAI)-1, being a classical TGFβ regulated gene,
was analyzed, similar to the other genes. PAI-1 was signif-
icantly upregulated by TGFβ in all fibroblast samples
tested.
Real time PCR
Fibroblast total RNA was isolated using the RNeasy mini
kit (Qiagen). RNA quantity and quality (OD 260/280)
were determined by optical density measurements on the
Nanodrop. Total RNA was treated with DNase I during
RNA isolation and run over the column to remove
genomic DNA (Qiagen RNA-se free DNAse set). Three ng
mRNA was transcribed into cDNA by reverse transcriptase
II (Invitrogen, Breda, the Netherlands). Real time PCR was
performed on an ABI7900 HT sequencer with "Assay on
Demands" from Applied Biosystems (Foster City, CA,
USA), according to the manufacturers' instructions.
Expression of the following genes was analyzed: Smad2,
3, 4, 7, versican, biglycan, and decorin. Data were ana-
lyzed by the delta-delta-Ct method [25]. In brief, concen-
tration in time (Ct) values of the genes of interest were
corrected for Ct values from a housekeeping gene, result-
ing in a delta-Ct value. In case of stimulation, the
obtained delta-Ct was normalized to the delta-Ct of the
non-stimulated sample value at the same time point
(delta-delta-Ct). The 2-delta-delta-Ct was taken for each stim-
ulated fibroblast sample, which was compared to its
unstimulated counterpart and presented as a percentage
of this basal value; each basal values was set to 100%. Sev-
eral housekeeping genes were tested for the influence of
the experimental procedure on the expression. Ribosomal
protein S9 was chosen as most optimal household gene
because gene expression was most stable under basal as
well as stimulation conditions.
Statistical analysis
Differences in subject characteristics and real time data
between the gene expression at basal levels were analyzed
using the Kruskal-Wallis test followed by the Mann-Whit-
ney U test. Differences between gene expression after stim-
ulation were analyzed using the Wilcoxon signed rank
test. To analyze differences between COPD- and control
fibroblasts, we calculated the percent change from the
stimulated value as compared to the basal value. Signifi-
cant differences in this percent change between COPD
fibroblasts and controls were also analyzed using the
Kruskal-Wallis test followed by a Mann-Whitney U test.
The level of significance used was < 0.05, all reported P-
values are two-sided.
Results
Influence of TGFβ, TNF, and CSE on Smad pathway 
related gene expression in fibroblasts
Healthy individuals
TGFβ stimulation
Downregulation of Smad3 gene expression occurred at
24-hour stimulation, while Smad2, Smad4, biglycan and
versican gene expression were upregulated (figures 2 and
3; additional file 1). Smad7 gene expression was upregu-
lated by TGFβ at both 1-hour and 24-hour stimulation.
TNF stimulation
Upregulation of Smad2 and 7 gene expression occurred at
24-hour stimulation. Smad4 was upregulated at both 1-
hour and 24-hour stimulation. Biglycan was downregu-
Table 1: Characteristics of the control and patient groups
Control Stage II Stage IV
Number of subjects 5 9 9
Age (years) 62 (36–63) 70 (44–81) 55 (44–61)
Smoking (Ex/C) 2/3 5/4 9/0
Pack-years 13 (0–75) 30 (8–58) 30 (17–54)
FEV1 % predicted 86 (83–108) 73 (50–76) 19 (13–29)
FEV1/FVC % pred 73 (70–81) 55 (37–68) 35 (24–66)
All values are presented as median values with ranges in parentheses. 
Ex = ex smokers, not smoking for at least one year, C = current 
smokers; FEV1 % predicted = Forced Expiratory Volume in 1 second 
as percentage of predicted value; FVC = forced vital capacity; pred = 
predicted. Stage means severity of COPD according to GOLD 
criteria.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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lated after 1 hour. Versican gene expression was downreg-
ulated at 24-hour stimulation (figures 2 and 3).
CSE
No effect on Smad genes occurred. The genes for biglycan,
decorin, and versican were downregulated after 1 hour of
exposure, without an effect at 24 hours.
COPD GOLD stage II patients
TGFβ stimulation
Whereas Smad3 gene expression in COPD stage II fibrob-
lasts was significantly downregulated at 1- and 24-hour
stimulation (figures 2 and 3; additional file 1), Smad4
and Smad7 gene expression was upregulated, Smad2 was
upregulated only at 24 hours. Decorin gene expression
was significantly downregulated at 24-hour stimulation,
whereas biglycan and versican gene expression was upreg-
ulated at 24 hours.
TNF stimulation
All Smads were significantly upregulated at 24 hours.
Decorin expression was downregulated at both 1- and 24-
hour stimulation. Biglycan gene expression was downreg-
ulated at 1 hour and versican gene expression was down-
regulated at 24 hours.
CSE exposure
Smad3 and decorin gene expression was downregulated at
1 hour. Smad4, decorin and biglycan gene expression was
downregulated at 24 hours. Smad7 gene expression was
upregulated at 24-hour stimulation.
Smad2, 3, 4 and 7: Results of real-time PCR analysis at 1 and 24 h, presented for control and disease stage, per stimulation Figure 2
Smad2, 3, 4 and 7: Results of real-time PCR analysis at 1 and 24 h, presented for control and disease stage, per stimulation. Val-
ues are based on 2-delta-delta-Ct values and represent the median percentages compared to the basal value before each stimula-
tion (basal set to 100%). Asterisks indicate significant change compared to basal values. St II = GOLD stage II, St IV = GOLD 
stage IV.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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COPD GOLD stage IV patients
TGFβ stimulation
Smad3 gene expression was downregulated at both time
points, while Smad7 gene expression was upregulated;
Smad4 was upregulated at 1 hour. Biglycan gene expres-
sion was downregulated at 1 hour, whereas biglycan and
versican gene expression was upregulated at 24-hour
TGFβ stimulation.
TNF stimulation
TNF resulted in upregulation of Smad2 gene expression at
24-hour stimulation.
CSE exposure
CSE exposure resulted in a downregulation of Smad3 gene
expression after 1 hour of stimulation, while biglycan
gene expression was also downregulated at that time
point. Smad4 and biglycan were downregulated and
Smad7 gene expression was upregulated at 24 hours after
CSE exposure.
Differences in Smad pathway gene expression between 
COPD and control fibroblasts
To specifically analyze the differential expression between
COPD fibroblasts and control fibroblasts, we calculated
the percentage change in gene expression after stimulation
from its basal value for each subject group. Subsequently
we checked for differences in strength of the stimulation
effect between controls and COPD fibroblasts by deter-
mining the difference between the change in gene expres-
sion from control fibroblasts when compared to stage II
and IV COPD fibroblasts, respectively (figure 4).
Decorin, biglycan and versican: Results of real-time PCR analysis at 1 and 24 h, presented for control and disease stage, per  stimulation Figure 3
Decorin, biglycan and versican: Results of real-time PCR analysis at 1 and 24 h, presented for control and disease stage, per 
stimulation. Values are based on 2-delta-delta-Ct values and represent the median percentages compared to the basal value before 
each stimulation (basal set to 100%). Asterisks indicate significant change compared to basal values. St II = GOLD stage II, St IV 
= GOLD stage IV.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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Without stimulation, gene expression levels were similar
between COPD and control fibroblasts. Smad2 and
Smad4 gene expression showed no differential expression
between COPD and control fibroblasts at all. Genes that
were differentially expressed between COPD and control
fibroblasts after stimulation with TGFβ, TNF or CSE are
depicted in figure 4. Smad3 gene expression decreased sig-
nificantly more in fibroblasts from COPD patients than
from controls at 1 hour after TNF as well as CSE exposure
(figure 4A). Smad7 gene expression was significantly
more increased in COPD than control fibroblasts after 24
hours CSE exposure (figure 4B). Versican gene expression
was significantly less decreased in COPD Stage II and IV
than control fibroblasts at 1 hour after CSE exposure (fig-
ure 4C). Decorin gene expression was significantly more
reduced in stage IV than the other group fibroblasts after
TGFβ-stimulation, whereas an increase was observed in
controls (figure 4D).
Discussion
We addressed the question whether genes of the Smad
pathway are aberrantly expressed in COPD fibroblasts
with and without TGFβ, TNF, and cigarette smoke extract
(CSE) stimulation. We provide suggestive evidence that
this is indeed the case. Since the Smad pathway coordi-
nates a delicate balance between fibrosis and excess ECM
destruction, alterations in this pathway can contribute to
the development of COPD. All investigated genes were
similarly expressed in control and COPD fibroblasts with-
out stimulation. In contrast, we observed a stimulus
dependent gene expression of the Smad pathway with dif-
ferential expression in COPD and control fibroblasts. In
particular Smad3 and Smad7 were aberrantly regulated in
COPD fibroblasts under influence of TNF and CSE (figure
4). Moreover, the ECM proteoglycans decorin and bigly-
can were downregulated in COPD fibroblasts after 24
hours of CSE exposure.
Little is known about the regulation of Smad and ECM
gene expression in lung tissue fibroblasts of COPD
Differential gene expression in COPD fibroblasts compared to control fibroblasts Figure 4
Differential gene expression in COPD fibroblasts compared to control fibroblasts. X-axis shows different stimuli, y-axis shows 
the percentage change of the 2-delta-delta-Ct values from the stimulation compared to basal expression. Basal gene expression did 
not significantly differ between stage II, stage IV, or control fibroblasts for each of the different genes and time points. * indi-
cates a significant difference between COPD and control fibroblasts.Respiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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patients by TGF-β, TNF, and CSE, factors that are of prime
importance in COPD development. We therefore first
investigated the regulation of the Smad pathway in con-
trol fibroblasts and observed that TGFβ stimulation in
general resulted in downregulation of Smad3 gene expres-
sion while Smad2, 4, 7, biglycan and versican gene expres-
sions were upregulated. This downregulation of Smad3
gene expression by TGFβ, together with the upregulation
of Smad7 supports an inhibitory feedback mechanism
because a reduced presence of Smad3 mRNA will result in
reduced levels of Smad3 protein, as suggested previously
[16]. Surprisingly, downregulation of Smad3 gene expres-
sion did not result in direct downregulation of ECM gene
expression, but in contrast biglycan and versican gene
expression was upregulated. This may be due to the fact
that there is sufficient Smad3 protein available within the
measured period of stimulation which subsequently acti-
vates ECM gene expression.
An unexpected finding was that TNF induced upregula-
tion of Smad2, 4 and 7 mRNA in control fibroblasts after
24-hrs, similar to TGFβ. Furthermore, TNF induced an
early downregulation of biglycan and later downregula-
tion of versican. TNF has been demonstrated to be able to
inhibit ECM production by fibroblasts [26]. This is in
accordance with the reduced biglycan and versican gene
expression in our control fibroblasts. Based on our previ-
ous findings we can conclude that TGFβ is known [11] to
have a stimulatory effect on the Smad pathway at the pro-
tein level, yet this effect is less clear for Smad-gene expres-
sion. As Smad proteins are rather stable intracellular
proteins, stimulation of the Smad pathway may result in
downstream increased production of extracellular matrix
proteins without necessarily a direct upregulation of
Smad-gene expression. However, the increased ECM pro-
tein end-product may lead to a negative feedback loop
that affects the gene expression level. Furthermore, also
the effect on the balance between the stimulating and
inhibiting Smad gene products is of importance in rela-
tion to the actual resulting ECM production.
The second research question we addressed is whether the
Smad pathway is differentially expressed under basal con-
ditions in fibroblasts of COPD patients and control sub-
jects. We observed no significant differences between the
groups suggesting that the altered modulation of the ECM
as observed in COPD is not due to intrinsic differences in
basal expression levels of the Smad pathway genes in
fibroblasts. We can not rule out that the basal gene expres-
sion is normalized due to culturing of the fibroblasts for
several passages. However, our data show that these
fibroblasts are still capable of responding to stimuli and
this particularly uncovers the differential fibroblast
response in COPD patients and controls.
The third question we addressed is whether the differences
in ECM modulation as observed in COPD can be ascribed
to a differential modulation of the Smad pathway under
influence of COPD relevant cytokines and cigarette
smoke, the most important etiologic risk factor of COPD.
Stage II and IV COPD fibroblasts displayed up- and down-
regulation of Smad genes under influence of TGFβ and
TNF in the same direction as the control fibroblasts. As
CSE exposure mainly induced inhibition of expression, it
seems likely that a general effect may play a role, although
of course some of the presumed > 5000 cigarette smoke
compounds also may have a specific role affecting certain
receptors or downstream mediators. Importantly, CSE
exposure induced differential effects on Smad4 and 7, and
biglycan and decorin gene expression of COPD fibrob-
lasts, findings that were not or only transiently observed
in control fibroblasts. Apparently, fibroblasts of COPD
patients are more reactive to components of cigarette
smoke extract. Of importance to the pathogenesis of
COPD, CSE blocked the repair effect of COPD pulmonary
fibroblasts, as represented by a decreased Smad3 gene
expression at 1 hour and Smad 4 expression at 24 hour,
together with the elevated Smad7 gene expression at 24
hours. It has been demonstrated that CSE is capable to
upregulate the expression of GADD34, a cell cycle related
protein [27]. The inhibitory effect of Smad7 on Smad2
and/or Smad3 phosphorylation is most likely mediated
via GADD34 [28]. This indicates that CSE is capable to
induce decreased Smad2 and Smad3 activation by
dephosphorylation of the TGFβ receptor I and thus is
indirectly capable of inhibiting the ECM gene transcrip-
tion. This is compatible with the observation that Smad3
deficiency in mouse knock-out models results in abnor-
mal lung alveolarization resembling emphysema [29,30].
We also found increased expression of Smad7, the inhib-
itor of ECM production that can also be involved in pro-
inflammatory actions [31,32]. Thus, it seems likely that
ongoing smoking in susceptible individuals leads to con-
tinuous suppression of Smad3 activation and continuous
stimulation of Smad7 gene expression, explaining chronic
local suppression of tissue repair.
In contrast to the increased Smad7gene expression in our
lung tissue fibroblasts, we previously demonstrated a
reduced expression of Smad7 protein in bronchial epithe-
lial cells of COPD patients compared to control subjects
[33]. In addition, Springer et al. demonstrated a reduced
Smad7 gene expression in bronchial biopsies of stage II
COPD patients. This may be indicative for the fibrotic
processes observed in COPD airways [34]. Springer and
coworkers incubated a bronchial epithelial cell line with
CSE for 48 hours and found a reduced Smad7 under these
conditions, and concluded that cigarette smoke is a reduc-
ing factor for Smad7 expression [34]. Apparently, Smad7
regulation is dependent on the cell type and/or on theRespiratory Research 2008, 9:83 http://respiratory-research.com/content/9/1/83
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duration of stimulation because we found an increase in
Smad7 gene expression in our primary parenchymal
fibroblasts after 24 hours under influence of CSE.
Together, the results of their study and ours match the
outcome of fibrosis in the airways and excess ECM
destruction in the parenchyma as observed in emphy-
sema.
Lung fibroblasts from COPD patients as well as controls
showed an upregulation of biglycan and versican gene
expression after 24-hour TGFβ stimulation. This indicates
that lung fibroblasts of COPD patients are capable of
upregulating ECM genes on gene expression level, and the
results depend on the effects of the local cytokine micro-
environment and the presence of cigarette smoke. Of
interest, and compatible with our previous observations,
decorin gene expression was mainly downregulated in
COPD fibroblasts, a finding that occurred with all stimuli,
and only transiently at 1 hour after CSE in control fibrob-
lasts. This highlights the putative important role of deco-
rin in COPD.
Obviously our data are a first set of experiments that now
need expansion at the protein level and including addi-
tional kinetic data. There are some limitations to our
study since our experiments were focused on intracellular
regulation, and hence it is not always clear whether the
direction of the modulation is a direct result of the
applied stimulus or the result of a cellular counteraction,
as a response to upregulation of other cellular factors by
this applied stimulus. Therefore, our data is conclusive as
to our hypothesis that there is an aberrant regulation of
the Smad pathway, but it is only supportive as to any con-
clusion of the exact underlying nature of this aberrant reg-
ulation.
In conclusion, our study in control and COPD fibroblasts
shows similar regulation of the Smad pathway in COPD
and controls without stimulation, but differential effects
of particularly cigarette smoke on fibroblast expression of
the Smad-genes, an intracellular pathway that is involved
in regulation of ECM gene expression. TGFβ, TNF, and
CSE cause differential downregulation of decorin gene
expression in COPD patients, at least partially via the
Smad pathway. Our findings may explain why only a sub-
set of smokers demonstrates an excess parenchymal ECM
destruction under influence of cigarette smoking. Smad3,
4 and 7 have to be considered as important factors in the
defective repair process of COPD fibroblasts, since smoke
exposure affects expression of these genes in COPD but
not in control fibroblasts. Because of the chronicity of
COPD in combination with its slow progression, even
subtle differences in this pathway can have a great impact
in the outcome of the disease.
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